CN111093671A - 以托吡坦对特应性皮炎的改进治疗 - Google Patents

以托吡坦对特应性皮炎的改进治疗 Download PDF

Info

Publication number
CN111093671A
CN111093671A CN201880059276.3A CN201880059276A CN111093671A CN 111093671 A CN111093671 A CN 111093671A CN 201880059276 A CN201880059276 A CN 201880059276A CN 111093671 A CN111093671 A CN 111093671A
Authority
CN
China
Prior art keywords
patient
toppitant
dose
genotype
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880059276.3A
Other languages
English (en)
Chinese (zh)
Inventor
M·H·波利梅洛伯罗斯
肖长福
G·比尔茨尼克斯
A·海特曼
S·斯迈斯泽克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanda Pharmaceuticals Inc
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of CN111093671A publication Critical patent/CN111093671A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Physical Education & Sports Medicine (AREA)
CN201880059276.3A 2017-09-13 2018-08-30 以托吡坦对特应性皮炎的改进治疗 Pending CN111093671A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762558303P 2017-09-13 2017-09-13
US62/558,303 2017-09-13
US201762572456P 2017-10-14 2017-10-14
US62/572,456 2017-10-14
PCT/US2018/048825 WO2019055225A1 (en) 2017-09-13 2018-08-30 ENHANCED TREATMENT OF ATOPIC DERMATITIS USING TRADIPITANT

Publications (1)

Publication Number Publication Date
CN111093671A true CN111093671A (zh) 2020-05-01

Family

ID=63684468

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880059276.3A Pending CN111093671A (zh) 2017-09-13 2018-08-30 以托吡坦对特应性皮炎的改进治疗

Country Status (11)

Country Link
US (1) US11549147B2 (https=)
EP (2) EP3681505B1 (https=)
JP (1) JP7347743B2 (https=)
KR (2) KR20250036264A (https=)
CN (1) CN111093671A (https=)
AU (1) AU2018331267B2 (https=)
CA (1) CA3073998A1 (https=)
CL (1) CL2020000655A1 (https=)
IL (1) IL272949B2 (https=)
MX (2) MX2020002852A (https=)
WO (1) WO2019055225A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2824552T3 (es) 2015-03-04 2021-05-12 Vanda Pharmaceuticals Inc Método de tratamiento con tradipitant
CA3101210A1 (en) 2018-06-08 2019-12-12 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
KR20220145844A (ko) * 2020-02-25 2022-10-31 반다 파마슈티칼즈, 인코퍼레이티드. 트라디피탄트를 이용한 아토피 피부염의 개선된 치료
JP7791832B2 (ja) 2020-03-26 2025-12-24 バンダ・ファーマシューティカルズ・インコーポレイテッド トラジピタントによる下気道感染症の治療
EP3996169B1 (en) 2020-05-07 2025-02-26 LG Energy Solution, Ltd. High-nickel electrode sheet and method for manufacturing same
US20240350469A1 (en) 2021-08-31 2024-10-24 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
AU2023413130A1 (en) 2022-12-21 2025-06-05 Vanda Pharmaceuticals Inc. Methods of treatment with tradipitant

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016141341A1 (en) * 2015-03-04 2016-09-09 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW263498B (https=) 1993-11-10 1995-11-21 Takeda Pharm Industry Co Ltd
ES2307925T3 (es) 2002-04-26 2008-12-01 Eli Lilly And Company Antagonistas de los receptores de la taquiquinina.
AU2003230829B8 (en) 2002-04-26 2008-12-11 Eli Lilly And Company Triazole derivatives as tachykinin receptor antagonists
JP2004250329A (ja) 2002-12-26 2004-09-09 Dainippon Pharmaceut Co Ltd イサチン誘導体
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
BRPI0415010B8 (pt) 2003-10-24 2021-05-25 Lilly Co Eli formas cristalinas iv e v de {2-[1-(3,5-bis-trifluorometilbenzil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il)-(2-clorofenil)-metanona, (2-clorofenil)-[2-(2-hidróxi-2-piridin-4-il-vinil)piridin-3-il]metanona, seus processos de preparação, e composição farmacêutica sólida
JP4673068B2 (ja) 2005-01-19 2011-04-20 独立行政法人科学技術振興機構 Ｔｈ１型アレルギー疾患治療用組成物
DE102005006217B4 (de) 2005-02-07 2007-08-16 Universitätsklinikum Hamburg-Eppendorf Diagnose von allergischen Erkrankungen und/oder atopischen Erkrankungen durch Nachweis von Autoantikörpern gegen CD28 in humanem Serum
EP1996179A2 (en) 2006-02-22 2008-12-03 Valorisation-Recherche, Limited Partnership Compositions for disorders associated with metachromatic cell activation
BRPI0721069A2 (pt) 2006-12-20 2014-02-04 Lilly Co Eli Intermediários e processo útil na preparação de {2-[1-(3,5-bis-trifluorometil-benzil)-5-piridin-4-il-1h[1,2, 3]triazol-4-il]-piridin-3-il}-2-clorofenil)-metanona
JP6644328B2 (ja) 2013-02-28 2020-02-12 ロート製薬株式会社 アトピー性疾患の発症又は重症化リスクの評価法
CA2915474A1 (en) 2013-06-24 2014-12-31 Tigercat Pharma, Inc. Use of nk-1 receptor antagonist serlopitant in pruritus
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016141341A1 (en) * 2015-03-04 2016-09-09 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VANDA PHARMACEUTICALS: "NCT02651714", 《CLINICALTRIALS.GOV》 *

Also Published As

Publication number Publication date
EP3681505C0 (en) 2024-12-18
IL272949A (en) 2020-04-30
CA3073998A1 (en) 2019-03-21
RU2020112222A (ru) 2021-10-13
WO2019055225A1 (en) 2019-03-21
MX2024004377A (es) 2024-04-26
CL2020000655A1 (es) 2020-10-09
EP3681505A1 (en) 2020-07-22
JP2020533381A (ja) 2020-11-19
EP4487912A3 (en) 2025-03-26
KR20250036264A (ko) 2025-03-13
AU2018331267A1 (en) 2020-04-16
IL272949B1 (en) 2025-03-01
US20210062262A1 (en) 2021-03-04
EP4487912A2 (en) 2025-01-08
US11549147B2 (en) 2023-01-10
IL272949B2 (en) 2025-07-01
BR112020004964A2 (pt) 2020-09-15
KR20200054232A (ko) 2020-05-19
JP7347743B2 (ja) 2023-09-20
MX2020002852A (es) 2020-07-22
AU2018331267B2 (en) 2024-03-07
EP3681505B1 (en) 2024-12-18

Similar Documents

Publication Publication Date Title
CN111093671A (zh) 以托吡坦对特应性皮炎的改进治疗
Yoshida et al. Skin barrier defects in atopic dermatitis: from old idea to new opportunity
JP6891385B2 (ja) トラジピタントによる治療方法
Cogo et al. Increased serum QUIN/KYNA is a reliable biomarker of post-stroke cognitive decline
EP4005570B1 (en) Pridopidine for use in treating rett syndrome
Kilpinen et al. Efficacy of two low-dose oral tylosin regimens in controlling the relapse of diarrhea in dogs with tylosin-responsive diarrhea: a prospective, single-blinded, two-arm parallel, clinical field trial
Landsberg et al. Effects of clomipramine on cats presented for urine marking
TW202110451A (zh) 使用布魯頓酪胺酸激酶抑制劑治療休格倫氏症候群之方法
JP2017529321A (ja) 炎症性腸疾患を診断ならびに処置するための方法および組成物
Morales-Mulia Intra-accumbal orexin-1 receptor inhibition prevents the anxiolytic-like effect of ethanol and leads to increases in orexin-A content and receptor expression
CN119318706A (zh) Nr3a作为蛋白靶点在筛选或制备预防和/或治疗抑郁样行为的药物中的应用
US20230073637A1 (en) Treatment of atopic dermatitis with tradipitant
Sala-Cunill et al. The role of mast cells mediators in angioedema without wheals
RU2812890C2 (ru) Усовершенствованное лечение атопического дерматита традипитантом
RU2793237C2 (ru) Усовершенствованное лечение атопического дерматита традипитантом
Larsson et al. Effects of 5-lipoxygenase inhibitor zileuton on airway responses to inhaled swine house dust in healthy subjects
BR112020004964B1 (pt) Método para determinar uma dose eficaz de tradipitant ou um sal farmaceuticamente aceitável do mesmo
CA3169449A1 (en) Improved treatment of atopic dermatitis with tradipitant
Mahmoud et al. Trimetazidine Attenuates Ulcerative Colitis-Linked Extrapyramidal Dysfunction by Mediated Dectin-1/LRRK2/α-Synuclein Autophagy Axis
Spears et al. Factors influencing individual variability in the therapeutic response to corticosteroids in asthma
Fonseca et al. 6ER-014 Analysis of the evolution of interleukin-6 in COVID-19 patients after being treated with dexamethasone
Wang et al. The effects of Kai-Xin-San in alleviating chronic social defeat stress-induced depression-like behaviors are associated with CD4+ T cells.
Samaka et al. Nucleocytoplasmic expression of autophagy-related protein 7 in psoriasis.
Xu et al. BML-111 inhibit H
HK40118605A (zh) 下尿路慢性炎症的治疗和诊断

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination